Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with semaglutide 2.4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial Frias JP, Deenadayalan S, Erichsen L, et al
The medication is prescription-only and may only be dispensed following a medical diagnosis, counselling, and treatment decision
22nd St
Semaglutide, a GLP-1 receptor agonist originally developed for type 2 diabetes, has demonstrated remarkable weight loss effects in clinical trials, with patients losing up to 22% of their body weight over 68 weeks
Improves Blood Sugar Control (Glucose Regulation) It stimulates insulin secretion when blood sugar levels are high and reduces excess glucagon release